Procter & Gamble director Craig Arnold acquired 1,438 restricted stock units on October 13, 2026, under The Procter & Gamble 2025 Stock and Incentive Compensation Plan. This was a compensation-related award, not a market purchase. After the award, he directly held 4,474 shares of common stock.
Procter & Gamble director Bertrand Marc Allen received an award of 1,438 restricted stock units on October 13, 2026, under The Procter & Gamble 2025 Stock and Incentive Compensation Plan. His reported direct position afterward was 12,698 shares; the total includes dividend equivalents granted as restricted stock units.
The Procter & Gamble Company (PG) declared a quarterly dividend of $1.0885 per share on its common stock and Series A and Series B ESOP Convertible Class A Preferred Stock. It is payable on or after November 16, 2026, to common shareholders of record at the close of business on October 23, 2026, and preferred shareholders of record at the start of business that day.
Preliminary results show shareholders elected all 12 director nominees, voted in favor of proposals to ratify the independent registered public accounting firm and hold an advisory vote on executive compensation, and voted against three shareholder proposals. The results remain preliminary until tabulated and certified by the independent Inspector of Elections. P&G said it has paid dividends for 136 consecutive years and increased them for 70 consecutive years.
Procter & Gamble Chief Financial Officer Andre Schulten sold 3,914 common shares on October 5, 2026, at $145.34 per share. A footnote says the shares were sold to cover tax obligations upon settlement of a Restricted Stock Unit Award. After the transaction, he directly held 65,618 shares. The reported indirect position through the Retirement Plan Trustee was 7,604 shares, reflecting an adjustment to PST through September 30, 2026.
Procter & Gamble CEO- Health Care Paul Gama sold 2,225 common shares at $145.34 per share on October 5, 2026, to cover a tax obligation upon settlement of a Restricted Stock Unit award. After the sale, he directly held 51,124 common shares. A separate indirect holding through the Retirement Plan Trustee was 1,184 shares; that amount reflects an adjustment to PST through September 30, 2026. No Rule 10b5-1 plan is reported.
Procter & Gamble Chief Legal Officer and Secretary Susan Street Whaley reported selling 2,369 common shares on October 5, 2026, at $145.34 per share. The shares were sold to cover tax obligations upon settlement of a restricted stock unit award. Whaley held 30,730 shares directly after the sale. A separate entry lists 7,254 shares indirectly through the Retirement Plan Trustee; the entry reflects an adjustment to PST through September 30, 2026.
Procter & Gamble reported that Chief Legal Officer & Secy Susan Street Whaley received 24,330 stock options to buy common shares, with a $143.95 exercise price; they are scheduled to become exercisable October 1, 2029, and expire October 1, 2036. She was also awarded 6,110 Restricted Stock Units under The Procter & Gamble 2025 Stock and Incentive Compensation Plan, bringing her reported direct common-stock holdings to 33,099 shares. A separate entry lists 7,188 shares held indirectly by a Retirement Plan Trustee.
Procter & Gamble reported that Chief Financial Officer Andre Schulten was awarded 78,324 stock options and 6,557 restricted stock units on October 1, 2026. The options have a $143.95 exercise price, are exercisable on October 1, 2029, and expire October 1, 2036; the restricted stock units were awarded under The Procter & Gamble 2025 Stock and Incentive Compensation Plan. Following the awards, Schulten’s direct common stock holdings were 69,532 shares; 7,535 shares were held indirectly by the Retirement Plan Trustee.
Procter & Gamble’s CEO- Health Care, Paul Gama, received an award of 12,517 restricted stock units on October 1, 2026, under The Procter & Gamble 2025 Stock and Incentive Compensation Plan. After the award, his reported direct common-stock holdings were 53,349 shares. A separate position lists 1,173 common shares held indirectly by the Retirement Plan Trustee.
Procter & Gamble CEO Shailesh Jejurikar received 16,065 restricted stock units on October 1, 2026, under The Procter & Gamble 2025 Stock and Incentive Compensation Plan, and a stock-option award covering 191,909 common shares. His reported direct common stock holdings after the RSU award were 55,391 shares. As of October 1, 2026, his reported indirect common stock holdings included 3,742 shares through a retirement plan trustee, 19,757 shares in Sankhya S Jejurikar Revocable Trust and 35,836 shares in Shailesh Jejurikar Trust.